Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Bachem Holding AG ( (CH:BANB) ) is now available.
Bachem has announced that Chief Commercial Officer Torsten Wöhr will leave the company to pursue a new professional opportunity, prompting a reshuffle at the top of the organization. Effective May 25, 2026, CEO Anne‑Kathrin Stoller will temporarily assume the CCO role in addition to her chief executive duties until a permanent successor is named.
Management highlighted Wöhr’s pivotal role in building Bachem’s oligonucleotide business and strengthening its position as a global contract manufacturing partner in the peptide market, underscoring his influence on sales and customer relationships. The board emphasized that Stoller’s previous experience as CCO should ensure a smooth transition and continuity in client relations, aiming to stabilize commercial operations and reassure stakeholders during the leadership change.
The most recent analyst rating on (CH:BANB) stock is a Hold with a CHF65.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.
More about Bachem Holding AG
Bachem Holding AG is a Swiss-listed, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides for pharmaceutical and biotechnology clients. Headquartered in Switzerland with sites in Europe, the U.S., and Asia, it supplies products for research, clinical development, and commercial use, leveraging more than 50 years of industry expertise and an international footprint.
The group positions itself as a global contract development and manufacturing partner, offering a comprehensive service range across the value chain for peptide and oligonucleotide therapeutics. Its long-standing experience and global presence support collaborations with drug developers worldwide and underpin its role as a key supplier in these fast-growing segments of the life sciences industry.
Average Trading Volume: 138,536
Technical Sentiment Signal: Strong Buy
Current Market Cap: CHF5.31B
For detailed information about BANB stock, go to TipRanks’ Stock Analysis page.